Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
EGF816 + Targeted Agents for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1
Toronto, Ontario
This trial is testing the safety and effectiveness of adding different drugs to EGF816 in order to treat advanced EGFR-mutant NSCLC.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.